Tempus AI Stock Surges on External Factors, Caution Ahead

Tempus AI's stock price surged by 9.1% on August 21, its third consecutive day of significant gains. The S&P 500 added only 0.4% in the same session, while peers Guardant Health, Natera, and IQVIA gained between 1.5% and 2.2%. This move was largely attributed to external factors rather than any news from Tempus itself.

The catalyst for this surge is believed to be a clinical-trial headline from Merck and Moderna, published earlier in the week. However, Tempus's business with drugmakers involves licensing de-identified data drawn from its therapy selection and liquid biopsy tests, which has been growing steadily. In the March 2026 quarter, this segment of the business booked $87 million in revenue, up 40.5% year-over-year.

Tempus management has deliberately metered the volume of Minimal Residual Disease (MRD) testing to manage reimbursement and losses. With the company's recent acquisition of Personalis, the brake on MRD testing volume is shifting from an external partner to an internal balance sheet. Tempus reported its first GAAP profit in August 2026, with a net margin still at -17.8% on a trailing twelve-month basis.

Despite this growth, investors are cautious about re-rating the stock until profits are consistently achieved. The company's guidance for calendar 2026 revenue has been raised to $1.595 billion to $1.605 billion, and whether this guide keeps climbing is worth watching from here.